fC6MQX

Poster Presentations – Sunday, October 19, 3:30 pm - 7:00 pmP439. Clinical Characteristics and Natural History of Crohn’s DiseasePatients With Endoscopic Skipping of Distal Terminal Ileum on IleoscopyParakkal Deepak, MBBS, Joel Fletcher, MD, Jeff Fidler, MD, SunilSamuel, MBBS, PhD, Edward Loftus, MD, FACG, John Barlow, MD,Stephanie Hansel, MD, Brenda Becker, BSc, Ishrat Mansuri, MBBS,David Bruining, MD, Division of Gastroenterology and Hepatology,Mayo Clinic, Rochester, MN, Department of Radiology, Mayo Clinic,Rochester, MN, Division of Gastroenterology and Hepatology,Nottingham University Hospitals NHS Trust, Nottingham, UnitedKingdom, Division of Pediatric Gastroenterology and Hepatology, MayoClinic, Rochester, MNP440. CD4 Count Does Not Impact Disease Severity in HIV PositivePatients With Ulcerative ColitisMeira Abramowitz, MD, Rajesh Ramachandran, MD, Charles Koczka,MD, Garrett Lawlor, MD, SUNY Downstate Medical Center, Brooklyn,NY, VA Harbor Health System, Brooklyn, NYP441. Hispanic Ethnicity Is Associated With Milder Disease Severity inCrohn’s Disease but Not Ulcerative ColitisChristie Choi, MD, Amit Singal, MD, MS, Kunjali Padhya, MD, AvegailFlores, MD, Prabhakar Swaroop, MD, Ezra Burstein, MD, TasneemAhmed, DO, Digestive Diseases, University of Texas SouthwesternMedical Center, Dallas, TXP442. Vedolizumab Induces Clinical Response and Remission Across aRange of Baseline Fecal Calprotectin Levels in Patients With UlcerativeColitis: Results From GEMINI 1Tim Wyant, PhD, James Lewis, MD, FACG, Walter Reinisch, MD,PhD, Themistocles Dassopoulos, MD, Philip Ginsburg, MD, FACG,Bruce Sands, MD, FACG, Brian Feagan, MD, FACG, Silvio Danese,MD, PhD, Arne Roseth, MD, PhD, Maria Rosario, PhD, HuyuanYang, PhD, Asit Parikh, MD, PhD, Brian Bressler, MD, MS, FRCPC,Takeda Pharmaceuticals International Co., Cambridge, MA, PerelmanSchool of Medicine at the University of Pennsylvania, Philadelphia,PA, Department of Internal Medicine III, Medical University of Vienna,Vienna, Austria, Gastroenterology Division, Washington UniversitySchool of Medicine, St. Louis, MO, Gastroenterology Center ofConnecticut, Hamden, CT, Icahn School of Medicine at Mount Sinai,New York, NY, Robarts Research Institute, University of WesternOntario, London, ON, Canada, Istituto Clinico Humanitas, Milan, Italy,Lovisenberg Diaconal Hospital, Oslo, Norway, Takeda PharmaceuticalsInternational, Inc., Deerfield, IL, Division of Gastroenterology, Universityof British Columbia, Vancouver, BC, CanadaP443. Clinical Benefit of Adalimumab Dose Adjustment for Patients WithModerately to Severely Active Crohn’s Disease in EXTENDJean-Frederic Colombel, MD, Paul Rutgeerts, MD, William Sandborn,MD, Douglas Wolf, MD, Walter Reinisch, MD, Gert Van Assche, MD,Samantha Eichner, MD, Qian Zhou, PhD, Joel Petersson, MD, AnneRobinson, MD, Roopal Thakkar, MD, Icahn School of Medicine atMount Sinai, New York, NY, University of Leuven, Leuven, Belgium,University of California San Diego, La Jolla, CA, Atlanta GastroenterologyAssociates, Atlanta, GA, McMaster University, Hamilton, ON, Canada,AbbVie Inc, North Chicago, ILP444. Improvement of C-Reactive Protein in Certolizumab PegolResponders but Not in Non-Responders in Crohn’s DiseaseDouglas Wolf, MD, FACG, Christine Wolf, MD, Atlanta GastroenterologyAssociates, Atlanta, GAP445. Evaluation of an Interim Crohn’s Disease Outcome Measure(PRO−2) Based on 2 Patient-Reported Components (Stool Frequency,Abdominal Pain) of the Crohn’s Disease Activity Index (CDAI) in theUstekinumab CERTIFI StudyChristopher Gasink, MD, Joshua Friedman, PhD, Long long Gao,PhD, Daphne Chan, PhD, William Sandborn, MD, Brian Feagan, MD,Janssen R&D, LLC, Spring House, PA, University of California SanDiego, La Jolla, CA, Robarts Research Institute, London, ON, CanadaP446. Etrolizumab Population Pharmacokinetics (Pop PK) and CovariateAnalysis in Patients With Moderately to Severely Active Ulcerative Colitis(UC)Xiaohui (Tracey) Wei, PhD, Diana Luca, PhD, Yehong Wang, PhD,Sharon O’Byrne, MD, Rich Erickson, PhD, John Davis, PhD, MeinaTang, PhD, Genentech, Inc., South San Francisco, CAP447. Pregnancy Outcomes After Exposure to Certolizumab Pegol:Results From Safety SurveillanceUma Mahadevan, MD, Séverine Vermeire, MD, Douglas Wolf, MD,Frauke Förger, MD, John Cush, MD, Amanda Golembesky, PhD,Laura Shaughnessy, PhD, Dirk De Cuyper, PhD, Kristel Luijtens, PhD,Sarah Abbas, MD, Megan Clowse, MD, UCSF Medical Center, SanFrancisco, CA, University Hospitals Leuven, Leuven, Belgium, AtlantaGastroenterology Associates, Atlanta, GA, University of Bern, Bern,Switzerland, Baylor Research Institute and Baylor University MedicalCenter, Dallas, TX, UCB Pharma, Raleigh, NC, Duke University MedicalCenter, Durham, NCP448. Comparative Efficacy of Pharmacological Interventions for Post-Operative Prophylaxis After Surgical Resection in Crohn’s Disease: ASystematic Review and Network Meta-analysisSiddharth Singh, MD, Sushil Kumar Garg, MBBS, Darrell Pardi, MD,MS, FACG, Zhen Wang, PhD, Mohammad Murad, MD, MPH, EdwardLoftus, MD, FACG, Gastroenterology and Hepatology, Mayo Clinic,Rochester, MN, University of Minnesota, Minneapolis, MNP449. Idiopathic Inflammatory Demyelinating Disease of the CentralNervous System in Patients With Inflammatory Bowel DiseaseKara De Felice, MD, Martina Novotna, MD, William Faubion, MD,William Tremaine, MD, Orhun Kantarci, MD, Laura Raffals, MD, MayoClinic Gastroenterology and Hepatology, Rochester, MN, Mayo ClinicNeurology, Rochester, MNP450. The Usefulness of Capsule Enteroscopy and Patency in theManagement of Patients With Crohn’s DiseaseJoão Santos-Antunes, MD, Helder Cardoso, MD, Margarida Marques,MD, Amadeu CR Nunes, MD, Susana Lopes, MD, Guilherme Macedo,MD, PhD, Centro Hospitalar S. João, Porto, PortugalP451. Early Life Environment and Natural History of Inflammatory BowelDiseasesAbra Guo, BS, Robin Wilson, BS, Betsy Stevens, BS, Caitlin Russell,BS, MS, Melissa Cohen, BS, Holly Sturgeon, BS, MPH, CosmasGiallourakis, MD, Hamed Khalili, MD, MPH, Deanna Nguyen,MD, Jenny Sauk, MD, Ramnik Xavier, MD, PhD, Vijay Yajnik, MD,PhD, Ashwin Ananthakrishnan, MD, MPH, Gastrointestinal Unit,Massachusetts General Hospital, Boston, MAP452. Endoscopic Skipping of the Distal Terminal IIeum in PediatricCrohn’s DiseaseIshrat Mansuri, MBBS, Joel Fletcher, MD, Parakkal Deepak, MBBS,David Bruining, MD, Amy Kolbe, MD, Jeff Fidler, MD, Sunil Samuel,MBBS, PhD, Edward Loftus, MD, FACG, John Barlow, MD, StephanieHansel, MD, Brenda Becker, BSc, Jeanne Tung, MD, FACG, Divisionof Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester,MN, Division of Gastroenterology and Hepatology, Mayo Clinic,Rochester, MN, Department of Radiology, Mayo Clinic, Rochester,MN, Nottingham University Hospitals NHS Trust, Nottingham, UnitedKingdomP453. The Novel PillCam Crohn’s Disease Capsule Demonstrates SimilarDiagnostic Yield as Ileocolonoscopy in Patients With Active Crohn’sDisease: A Prospective Multicenter International Cohort StudyJonathan Leighton, MD, Debra Helper, MD, Pramod Malik, MD, RussellHavranek, MD, Kim Isaacs, MD, Iris Dotan, MD, Adi Lahat, MD, JohnHorlander, MD, Andrew Tinsley, MD, Ignacio Fernandez-Urien Sainz,MD, Bruno Rosa, MD, Gerrard Mullin, MD, Ian Gralnek, MD, MayoClinic, Scottsdale, AZ, Medicine, Indiana University School of Medicine,Indianapolis, IN, Gastroenterology Associates of Tidewater, Chesapeake,VA, Gastroenterology Clinic of San Antonio, San Antonio, TX, Universityof North Carolina, Chapel Hill, NC, Tel Aviv Sourasky Medical Center(Ichilov), Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel,Louisville Gastroenterology Associates, Louisville, KY, Penn StateHershey Medical Center, Hershey, PA, Hospital de Navarra, Pamplona,Spain, CentroHospitalar do Alto Ave, Guimaraes, Portugal, JohnsHopkins Medical Center, Baltimore, MD, Rambam Medical Center,Haifa, IsraelFor more information on ACG 2014 and to register, visit www.acgmeetings.gi.org.58